| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/21/2010 | US20100016254 Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| 01/21/2010 | US20100016253 Methods and compositions related to heightened apobec-1 related protein (arp) expression |
| 01/21/2010 | US20100016252 Mannich Base N-Oxide Drugs |
| 01/21/2010 | US20100016251 Nucleoside phosphoramidate prodrugs |
| 01/21/2010 | US20100016250 Toll-like receptor 9 agonists |
| 01/21/2010 | US20100016249 Cancer sensitizer comprising glucosamine, glucosamine derivatives or salts thereof |
| 01/21/2010 | US20100016248 Tablet formulation |
| 01/21/2010 | US20100016247 Using budding yeast to screen for inhibitors of aurora kinases |
| 01/21/2010 | US20100016246 Food composition for functional foods and nutritional supplements |
| 01/21/2010 | US20100016245 Rhamnose substituents of sl0101 and therapeutic uses thereof |
| 01/21/2010 | US20100016244 D-glucopyranose 1-[3,5-bis (1,1-dimethylethy)-4-hydroxybenzoate] and its derivatives, preparation and use thereof |
| 01/21/2010 | US20100016235 Inhibitors of Protein Phosphatase 1, GADD34 and Protein Phosphatase 1/GADD34 Complex, Preparation and Uses Thereof |
| 01/21/2010 | US20100016233 Heterocyclic Aromatic Compounds Useful As Growth Hormone Secretagogues |
| 01/21/2010 | US20100016224 Compositions and methods for modulating an immune response |
| 01/21/2010 | US20100016221 Method of degrading protein by chaperone-mediated autophagy |
| 01/21/2010 | US20100016214 Carbohydrates mixture |
| 01/21/2010 | US20100016213 Use of a diterpenoid compound for treating diabetes |
| 01/21/2010 | US20100016212 Methods for treating pulmonary hypertension and compositions comprising vasoactive intestinal peptide |
| 01/21/2010 | US20100016208 Photoactivatable antimicrobial agents |
| 01/21/2010 | US20100016207 Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid |
| 01/21/2010 | US20100015700 Use of the adenoviral e2 late promoter |
| 01/21/2010 | US20100015262 Novel use of compounds and combinations of compounds for improving the physical appearance |
| 01/21/2010 | US20100015261 Herbal preparation for sleep apnea relief |
| 01/21/2010 | US20100015255 Compositions and methods for treating hypercholesterolemia using ortanique peel extract |
| 01/21/2010 | US20100015253 Treatment of nail infections with no |
| 01/21/2010 | US20100015249 Antitumor agent containing 6'-amidino-2'-naphthyl 4-guanidinobenzoate or salt thereof |
| 01/21/2010 | US20100015247 Carrageenan based antimicrobial compositions |
| 01/21/2010 | US20100015240 Process for preparing microparticles containing bioactive peptides |
| 01/21/2010 | US20100015239 Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same |
| 01/21/2010 | US20100015237 NSAID Delivery from Polyarylates |
| 01/21/2010 | US20100015235 Compositions and methods for treating multiple sclerosis |
| 01/21/2010 | US20100015234 Pharmaceutical preparations and their manufacture |
| 01/21/2010 | US20100015232 Nanoparticles for nucleic acid delivery |
| 01/21/2010 | US20100015229 Pharmaceutical compositions |
| 01/21/2010 | US20100015225 Solid dispersion of a neurokinin antagonist |
| 01/21/2010 | US20100015224 Programmable buoyant delivery technology |
| 01/21/2010 | US20100015222 Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| 01/21/2010 | US20100015221 Orally rapid disintegrating tablet preparation comprising fat-soluble active ingredients |
| 01/21/2010 | US20100015220 Niacin and nsaid combination therapy |
| 01/21/2010 | US20100015219 Pharmaceutical compositions of active substances difficult to improperly divert from their intended route of administration |
| 01/21/2010 | US20100015218 Compositions and methods for potentiated activity of biologically active molecules |
| 01/21/2010 | US20100015216 Methods and materials for treating acne |
| 01/21/2010 | US20100015205 Biocompatible amino acid anhydride polymers |
| 01/21/2010 | US20100015203 Biocompatible fibrinogen matrix on a solid support |
| 01/21/2010 | US20100015201 Implant with coating |
| 01/21/2010 | US20100015200 Drug Delivery Medical Device |
| 01/21/2010 | US20100015195 Injectable depot compositions and it's process of preparation |
| 01/21/2010 | US20100015190 Preparation for reducing and/or preventing body fat and respective uses, in particular together with a dressing material |
| 01/21/2010 | US20100015183 Transmucosal delivery devices with enhanced uptake |
| 01/21/2010 | US20100015178 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase |
| 01/21/2010 | US20100015174 Method to control dengue viruses in humans by picolinic acid and derivatives thereof |
| 01/21/2010 | US20100015167 in vitro method of screening an individual for metastatic colorectal cancer cells or primary and/or metastatic stomach or esophageal cancer cells; vaccine comprising a protein that comprises human sucrase isomaltase protein |
| 01/21/2010 | US20100015160 Compositions and methods for diagnosing and treating endometriosis |
| 01/21/2010 | US20100015152 Diagnostic and therapeutic methods |
| 01/21/2010 | US20100015151 Polypeptides from neisseria meningitidis |
| 01/21/2010 | US20100015149 Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| 01/21/2010 | US20100015148 Methods and compositions for the utilization and targeting of osteomimicry |
| 01/21/2010 | US20100015147 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting GM1-ganglioside |
| 01/21/2010 | US20100015141 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| 01/21/2010 | US20100015140 Inhibitor Compounds and Cancer Treatment Methods |
| 01/21/2010 | US20100015135 Anti-ephb4 antibodies and methods using same |
| 01/21/2010 | US20100015130 Disc-1 pathway activators in the control of neurogenesis |
| 01/21/2010 | US20100015129 Methods of using F-spondin as a biomarker for cartilage degenerative conditions and bone diseases |
| 01/21/2010 | US20100015128 GRP78 as a Predictor of Responsiveness to Therapeutic Agents |
| 01/21/2010 | US20100015127 Treatment for demyelinating disease |
| 01/21/2010 | US20100015125 Methods and compositions for enhancing immune memory by blocking intrahepatic activated t cell deletion |
| 01/21/2010 | US20100015121 Inhibiting gs-fdh to modulate no bioactivity |
| 01/21/2010 | US20100015120 Hybrid protein that converts arachidonic acid into prostacyclin |
| 01/21/2010 | US20100015118 Supplement formula to prevent and deter muscle trauma and method of using same |
| 01/21/2010 | US20100015117 Compositions and methods for targeting a polypeptide to the central nervous system |
| 01/21/2010 | US20100015111 Methods And Kits For The Treatment Inhibition, And Maintenance Of Gastrointestinal Disorders |
| 01/21/2010 | US20100015108 Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| 01/21/2010 | US20100015107 Expression elements |
| 01/21/2010 | US20100015102 Composition for treatment of cartilage disease |
| 01/21/2010 | US20100015101 Novel tumor antigen peptides |
| 01/21/2010 | US20100015096 Fusion Proteins of Mycobacterium Tuberculosis |
| 01/21/2010 | US20100015095 Restoration of visual responses by in vivo delivery of rhodopsin nucleic acids |
| 01/21/2010 | US20100015094 Antiviral nucleoside analogs |
| 01/21/2010 | US20100015093 Methods and compositions of treating a flaviviridae family viral infection |
| 01/21/2010 | US20100015092 Quinoxalinyl macrocyclic hepatitis c serine protease inhibitors |
| 01/21/2010 | US20100015091 Modified stat1 transgene that confers interferon hyperresponsiveness, methods and uses therefor |
| 01/21/2010 | US20100015090 Administering a Hepatitis C virus NS3/4A protease inhibitor such as telaprevir and a cytochrome P450 monooxygenase inhibitor such as ritonavir |
| 01/21/2010 | US20100015086 Use of il-22 for the treatment of conditions of metabolic disorders |
| 01/21/2010 | US20100015085 Phase 2 inducers and related signaling pathways protect cartilage against inflammation/infection, apoptosis and stress |
| 01/21/2010 | US20100015084 Compounds for Treating Papilloma Virus Infection |
| 01/21/2010 | US20100015083 Method of producing pvp/fullerene complex and aqueous solution thereof |
| 01/21/2010 | US20100015080 Use of at least one (dihydro)jasmonic acid derivative for treating dry skin |
| 01/21/2010 | US20100015072 Topical Compositions Comprising Isonicotinamide |
| 01/21/2010 | US20100015065 Compositions for food, process for producing the same, and functional foods and drinks containing the same |
| 01/21/2010 | US20100015063 Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them |
| 01/21/2010 | US20100015061 Pharmaceutical Compositions Based on Anticholinergics and Andolast |
| 01/21/2010 | US20100015050 Peg and targeting ligands on nanoparticle surface |
| 01/21/2010 | US20100015049 Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents |
| 01/21/2010 | US20100015046 Camptothecin-Binding Moiety Conjugates |
| 01/21/2010 | US20100012132 Clear, washable lubricant compositions, and methods of making same |
| 01/21/2010 | US20100012118 Medicament dosage for inhaler |
| 01/21/2010 | DE102008015425A1 Kosmetische oder dermatologische Zubereitungen zur Verringerung von Juckreiz und anderen dermatologischen Missempfindungen, die insbesondere bei Altershaut auftreten können, mit einem Gehalt an (1R,2S,5R)-2-Isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethyl-cyclohexancarboxamid und/oder (1R,2S,5R)-N-(4-(Cyanomethyl)-phenyl)-2-isopropyl-5-methylcyclohexancarboxamid Cosmetic or dermatological preparations to reduce itching and other dermatological abnormal sensations that can occur with aging skin in particular, with a content of (1R, 2S, 5R) -2-isopropyl-5-methyl-N- (2- (pyridin-2- yl) ethyl-cyclohexanecarboxamide and / or (1R, 2S, 5R) -N- (4- (cyanomethyl) phenyl) -2-isopropyl-5-methylcyclohexancarboxamid |
| 01/21/2010 | DE10004815B4 Menschliche intestinale Natriumphosphat-Kotransporter Human intestinal sodium phosphate cotransporter |
| 01/21/2010 | CA2849218A1 Compositions and methods for treating disorders associated with overweight animals |
| 01/21/2010 | CA2768183A1 Targeted nitroxide agents |